CCM
PFE icon

Cribstone Capital Management’s Pfizer PFE Stock Holding History

Cribstone Capital Management’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$920K Buy
17,959
+742
+4% +$35.6K 0.54% 54
2022
Q3 		$753K Buy
17,217
+182
+1% +$8.84K 0.47% 62
2022
Q2 		$893K Buy
17,035
+496
+3% +$25.3K 0.55% 50
2022
Q1 		$856K Sell
16,539
-2,030
-11% -$105K 0.47% 54
2021
Q4 		$1.1M Buy
18,569
+4,899
+36% +$243K 0.61% 44
2021
Q3 		$588K Sell
13,670
-44
-0.3% -$1.95K 0.35% 66
2021
Q2 		$537K Sell
13,714
-97
-0.7% -$3.77K 0.33% 70
2021
Q1 		$500K Buy
13,811
+1,246
+10% +$44.2K 0.33% 70
2020
Q4 		$463K Sell
12,565
-95
-0.8% -$3.48K 0.32% 68
2020
Q3 		$441K Sell
12,660
-3,943
-24% -$138K 0.36% 68
2020
Q2 		$515K Buy
16,603
+988
+6% +$33.6K 0.43% 66
2020
Q1 		$484K Buy
15,615
+516
+3% +$17.6K 0.51% 55
2019
Q4 		$561K Sell
15,099
-7,278
-33% -$259K 0.5% 53
2019
Q3 		$763K Sell
22,377
-5,782
-21% -$210K 0.46% 57
2019
Q2 		$1.16M Sell
28,159
-824
-3% -$32.7K 0.63% 48
2019
Q1 		$1.17M Sell
28,983
-2,792
-9% -$112K 0.62% 44
2018
Q4 		$1.32M Sell
31,775
-1,697
-5% -$70.4K 0.67% 44
2018
Q3 		$1.4M Buy
33,472
+1,314
+4% +$50.6K 0.64% 45
2018
Q2 		$1.11M Buy
32,158
+2,110
+7% +$72.1K 0.54% 51
2018
Q1 		$1.01M Buy
30,048
+607
+2% +$20.9K 0.5% 56
2017
Q4 		$1.01M Buy
29,441
+527
+2% +$18K 0.48% 58
2017
Q3 		$979K Sell
28,914
-690
-2% -$22.2K 0.51% 58
2017
Q2 		$943K Buy
29,604
+643
+2% +$20.3K 0.51% 60
2017
Q1 		$937K Buy
28,961
+10,354
+56% +$326K 0.51% 62
2016
Q4 		$561K Sell
18,607
-372
-2% -$11.4K 0.34% 68
2016
Q3 		$590K Sell
18,979
-332
-2% -$11.1K 0.36% 65
2016
Q2 		$645K Sell
19,311
-265
-1% -$8.46K 0.4% 62
2016
Q1 		$551K Buy
19,576
+1,136
+6% +$32.4K 0.44% 60
2015
Q4 		$559K Buy
+18,440
New +$580K 0.46% 60

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cribstone Capital Management's PFE Position: Q4 2022 in Review

Cribstone Capital Management increased its Pfizer (PFE) stake by 4.3% in Q4 2022, buying an estimated $35.6K and bringing the position to 17,959 shares worth $920K. The position accounts for 0.54% of the portfolio, ranked #54.

Cribstone Capital Management first reported a position in PFE in Q4 2015 and has held it in 29 quarters since. The position peaked at $1.4M in Q3 2018. 3,265 funds tracked by Wall St. Rank hold PFE as of Q4 2022.

  • Cribstone Capital Management held 17,959 shares of Pfizer worth $920K as of Q4 2022.
  • Cribstone Capital Management bought 742 Pfizer shares in Q4 2022, an estimated $35.6K.
  • Pfizer made up 0.54% of Cribstone Capital Management's portfolio in Q4 2022, its #54 holding.
  • Cribstone Capital Management first reported a position in Pfizer in Q4 2015 and has held it in 29 quarters since.
  • Cribstone Capital Management's Pfizer position peaked at $1.4M in Q3 2018.
  • 3,265 funds tracked by Wall St. Rank held Pfizer as of Q4 2022.

Based on Cribstone Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.